Findings of Research Misconduct, 27904-27905 [2023-09355]
Download as PDF
27904
Federal Register / Vol. 88, No. 85 / Wednesday, May 3, 2023 / Notices
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–09356 Filed 5–2–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Johnny J. He, Ph.D. (Respondent), who
is a Professor, Department of
Microbiology and Immunology,
Rosalind Franklin University of
Medicine and Science (RFUMS).
Respondent engaged in research
misconduct in research reported in
grant applications submitted for U.S.
Public Health Service (PHS) funds,
specifically U01 DA056010–01 and DP1
DA056160–01 submitted to the National
Institute on Drug Abuse (NIDA),
National Institutes of Health (NIH), R01
AG078019–01 submitted to the National
Institute on Aging (NIA), NIH, and R35
NS127233–01 submitted to the National
Institute of Neurological Disorders and
Stroke (NINDS), NIH. The
administrative actions, including
supervision for a period of three (3)
years, were implemented beginning on
April 17, 2023, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Sheila Garrity, JD, MPH, MBA, Director,
Office of Research Integrity, 1101
Wootton Parkway, Suite 240, Rockville,
MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Johnny J. He, Ph.D., Rosalind Franklin
University of Medicine and Science:
Based on the report of an investigation
conducted by RFUMS, an admission by
Respondent, and analysis conducted by
ORI in its oversight review, ORI found
that Johnny J. He, Ph.D., Professor,
Department of Microbiology and
Immunology, RFUMS, engaged in
research misconduct in research
reported in grant applications submitted
for PHS funds, specifically U01
DA056010–01 and DP1 DA056160–01
submitted to NIDA, NIH, R01
AG078019–01 submitted to NIA, NIH,
and R35 NS127233–01 submitted to
NINDS, NIH.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, or recklessly falsifying,
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:32 May 02, 2023
Jkt 259001
fabricating, and plagiarizing
experimental data and text that
described the research from one (1) preprint and four (4) published papers and
represented the data and/or ideas as his
own under different experimental
conditions in four (4) NIH grant
applications and in one research record.
The falsified, fabricated, and plagiarized
research data and text appeared in the
following NIH grant applications:
• NIA, NIH, grant R01 AG078019–01,
‘‘iTat mice to model HIV-impaired
neurogenesis and accelerated aging,’’
submitted on September 7, 2021
• NIDA, NIH, grant U01 DA056010–01,
‘‘Single cell and spatial
transcriptomic changes of cocaine use
in the iTat HAND model,’’ submitted
on July 20, 2021
• NIDA, NIH, grant DP1 DA056160–01,
‘‘Targeting epigenetic changes to
understand and treat CUD in people
living with HAND,’’ submitted on
August 13, 2021
• NINDS, NIH, grant R35 NS127233–01,
‘‘HIV-associated neurocognitive
disorder: from mechanisms to
therapeutics,’’ submitted on July 13,
2021
The sources of the plagiarized images
and text were:
• Clin Transl Med. 2017 June 8;6(1):20.
doi: 10.1186/s40169–017–0150–9
(hereafter referred to as ‘‘Clin Trans
Med 2017’’)
• Sci Adv. 2019 October
16;5(10):eaax1532. doi: 10.1126/
sciadv.aax1532 (hereafter referred to
as ‘‘Sci Adv 2019’’)
• BioRxiv. March 5, 2020. doi:10.1101/
2020.02.29.970558v2 (hereafter
referred to as ‘‘BioRxiv 2020’’).
BioRxiv 2020 is a preprint version of
Nature. 2021 October
6;598(7879):103–110. doi: 10.1038/
s41586–021–03500–8
• Biosci Biotechnol Biochem. 2020
May;84(5):919–926. doi:10.1080/
09168451.2020.1714420 (hereafter
referred to as ‘‘BBB 2020’’)
• Front Oncol. 2021 January
19;10:607349. doi: 10.3389/
fonc.2020.607349 (hereafter referred
to as ‘‘Front Onc 2021’’)
Specifically, ORI found that
Respondent knowingly, intentionally, or
recklessly:
• falsified, fabricated, and plagiarized
research data and the text that described
the research by:
—using Figures 1A and 1B of BBB 2020,
representing wild-type and APP23
mice at 6 and 24 months, as the
Respondent’s own data in Figures 5A
and 5B of U01 DA056010–01 and
Figures 7A and 7B of R01 AG78019–
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
01, representing wild-type and iTat
mice at 6 and 12 months
—using Figures 3c and 3d of BioRxiv
2020, representing results in 60 days
old Snap25–IRES2–Cre mice crossed
to Ai14 mice, as the Respondent’s
own data in Figure 6 of U01
DA056010–01 and Figure 8 of R01
AG078019–01, representing results in
12-weeks old iTat mice
—using, cropping, and splicing Figures
5g–5i of BioRxiv 2020, representing
cell type transcription factors
networks signature of the regulatory
genome in neurons isolated from the
brains of Snap25–IRES2–Cre mice
crossed to Ai14 mice, as the
Respondent’s own data in one
research record intended for use in
preparing figures for incorporation in
U01 DA056010–01, representing
spatiotemporal atlas of gene
regulatory networks and biological
pathways in the brain during
neurogenesis and aging altered by Tat
expression and HIV infection
• fabricated and plagiarized research
data and text that described the research
by:
—using Figure 3 of Front Onc 2021 as
the Respondent’s own data in Figure
8 of U01 DA056010–01 and Figure 10
of R01 AG078019–01
• plagiarized text by:
—using a paragraph from Sci Adv 2019
as the Respondent’s own text
describing cocaine use disorder in the
section titled ‘‘The problem
description and a new therapeutic
strategy for CUD in people living with
HAND’’ of DP1 DA056160–01
—using a paragraph from Clin Trans
Med 2017 as the Respondent’s own
text describing single cell sequencing
in Specific Aim 2 of both U01
DA056010–01 and R01 AG078019–01
Dr. He entered into a Voluntary
Settlement Agreement (Agreement) and
voluntarily agreed to the following:
(1) Respondent will have his research
supervised for a period of three (3) years
beginning on April 17, 2023 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
E:\FR\FM\03MYN1.SGM
03MYN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 85 / Wednesday, May 3, 2023 / Notices
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of three (3) years
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6)-month
intervals setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract are
supported by the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude himself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
VerDate Sep<11>2014
18:32 May 02, 2023
Jkt 259001
Dated: April 28, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
[FR Doc. 2023–09355 Filed 5–2–23; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Community Health Aide Program:
Tribal Planning & Implementation
Announcement Type: New.
Funding Announcement Number:
HHS–2023–IHS–TPI–0001.
Assistance Listing (Catalog of Federal
Domestic Assistance or CFDA) Number:
93.382.
Key Dates
Application Deadline Date: August 1,
2023.
Earliest Anticipated Start Date:
September 15, 2023.
I. Funding Opportunity Description
Statutory Authority
The Indian Health Service (IHS) is
accepting applications for grants for the
Community Health Aide Program
(CHAP) Tribal Planning and
Implementation (TPI) program. The
CHAP is authorized under the Snyder
Act, 25 U.S.C. 13; the Transfer Act, 42
U.S.C. 2001(a); and the Indian Health
Care Improvement Act, 25 U.S.C. 1616l.
The Assistance Listings section of
SAM.gov (https://sam.gov/content/
home) describes this program under
93.382.
Background
The national CHAP will provide a
network of health aides trained to
support licensed health professionals
while providing direct health care,
health promotion, and disease
prevention services. These providers
will work within a referral relationship
under the supervision of licensed
clinical providers that includes clinics,
service units, and hospitals. The
program will increase access to direct
health services, including inpatient and
outpatient visits.
The Alaska CHAP has become a
model for efficient and high quality
health care delivery in rural Alaska
providing approximately 300,000
patient encounters per year and
responding to emergencies 24 hours a
day, 7 days a week. Specialized
providers in dental and behavioral
health were later introduced to respond
to the needs of patients and address the
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
27905
health disparities in oral health and
mental health amongst American
Indians and Alaska Natives.
The national CHAP is a workforce
model that includes three different
provider types that act as extenders of
licensed clinical supervisors. The
national CHAP currently includes a
behavioral health aide, community
health aide, and dental health aide.
Each of the health aide categories
operate in a tiered level practice system.
The national CHAP model provides an
opportunity for increased access to care
through the extension of primary care,
dental, and behavioral health clinicians.
In 2010, under the permanent
reauthorization of the Indian Health
Care Improvement Act (IHCIA),
Congress provided the Secretary of
Health and Human Services, acting
through the IHS, the authority to expand
the Alaska CHAP program. In 2016, the
IHS initiated Tribal Consultation on
expanding the CHAP to the contiguous
48 states. In 2018, the IHS formed the
CHAP Tribal Advisory Group (TAG) and
began developing the program. In 2020,
the IHS announced the national CHAP
policy, which formally created the
national CHAP.
Purpose
The purpose of the TPI program is to
support the planning and
implementation for Tribes and Tribal
Organizations (T/TO) positioned to
begin operating a CHAP or support a
growing CHAP in the contiguous 48
states. The program is designed to
support the regional flexibility required
to implement a CHAP unique to the
needs of individual Tribal communities
across the country through the
identification of feasibility factors. The
focus of the program is to:
1. Develop clinical supervisor support
for primary care, behavioral health, and
dental health clinicians providing both
direct and indirect supervision of
prospective health aides;
2. Identify area and communityspecific health care needs of patients
that can be addressed by the health
aides;
3. Identify and develop a technology
infrastructure plan for the mobility and
success of health aides in anticipation of
providing services;
4. Develop a training plan to include
partners across the T/TO’s geographic
region to enhance the training
opportunities available to prospective
health aides to include continuing
education and clinical practice;
5. Identify best practices for
integrating a CHAP workforce into an
existing Tribal health system;
E:\FR\FM\03MYN1.SGM
03MYN1
Agencies
[Federal Register Volume 88, Number 85 (Wednesday, May 3, 2023)]
[Notices]
[Pages 27904-27905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-09355]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Johnny
J. He, Ph.D. (Respondent), who is a Professor, Department of
Microbiology and Immunology, Rosalind Franklin University of Medicine
and Science (RFUMS). Respondent engaged in research misconduct in
research reported in grant applications submitted for U.S. Public
Health Service (PHS) funds, specifically U01 DA056010-01 and DP1
DA056160-01 submitted to the National Institute on Drug Abuse (NIDA),
National Institutes of Health (NIH), R01 AG078019-01 submitted to the
National Institute on Aging (NIA), NIH, and R35 NS127233-01 submitted
to the National Institute of Neurological Disorders and Stroke (NINDS),
NIH. The administrative actions, including supervision for a period of
three (3) years, were implemented beginning on April 17, 2023, and are
detailed below.
FOR FURTHER INFORMATION CONTACT: Sheila Garrity, JD, MPH, MBA,
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Johnny J. He, Ph.D., Rosalind Franklin University of Medicine and
Science: Based on the report of an investigation conducted by RFUMS, an
admission by Respondent, and analysis conducted by ORI in its oversight
review, ORI found that Johnny J. He, Ph.D., Professor, Department of
Microbiology and Immunology, RFUMS, engaged in research misconduct in
research reported in grant applications submitted for PHS funds,
specifically U01 DA056010-01 and DP1 DA056160-01 submitted to NIDA,
NIH, R01 AG078019-01 submitted to NIA, NIH, and R35 NS127233-01
submitted to NINDS, NIH.
ORI found that Respondent engaged in research misconduct by
intentionally, knowingly, or recklessly falsifying, fabricating, and
plagiarizing experimental data and text that described the research
from one (1) pre-print and four (4) published papers and represented
the data and/or ideas as his own under different experimental
conditions in four (4) NIH grant applications and in one research
record. The falsified, fabricated, and plagiarized research data and
text appeared in the following NIH grant applications:
NIA, NIH, grant R01 AG078019-01, ``iTat mice to model HIV-
impaired neurogenesis and accelerated aging,'' submitted on September
7, 2021
NIDA, NIH, grant U01 DA056010-01, ``Single cell and spatial
transcriptomic changes of cocaine use in the iTat HAND model,''
submitted on July 20, 2021
NIDA, NIH, grant DP1 DA056160-01, ``Targeting epigenetic
changes to understand and treat CUD in people living with HAND,''
submitted on August 13, 2021
NINDS, NIH, grant R35 NS127233-01, ``HIV-associated
neurocognitive disorder: from mechanisms to therapeutics,'' submitted
on July 13, 2021
The sources of the plagiarized images and text were:
Clin Transl Med. 2017 June 8;6(1):20. doi: 10.1186/s40169-017-
0150-9 (hereafter referred to as ``Clin Trans Med 2017'')
Sci Adv. 2019 October 16;5(10):eaax1532. doi: 10.1126/
sciadv.aax1532 (hereafter referred to as ``Sci Adv 2019'')
BioRxiv. March 5, 2020. doi:10.1101/2020.02.29.970558v2
(hereafter referred to as ``BioRxiv 2020''). BioRxiv 2020 is a preprint
version of Nature. 2021 October 6;598(7879):103-110. doi: 10.1038/
s41586-021-03500-8
Biosci Biotechnol Biochem. 2020 May;84(5):919-926.
doi:10.1080/09168451.2020.1714420 (hereafter referred to as ``BBB
2020'')
Front Oncol. 2021 January 19;10:607349. doi: 10.3389/
fonc.2020.607349 (hereafter referred to as ``Front Onc 2021'')
Specifically, ORI found that Respondent knowingly, intentionally,
or recklessly:
falsified, fabricated, and plagiarized research data and
the text that described the research by:
--using Figures 1A and 1B of BBB 2020, representing wild-type and APP23
mice at 6 and 24 months, as the Respondent's own data in Figures 5A and
5B of U01 DA056010-01 and Figures 7A and 7B of R01 AG78019-01,
representing wild-type and iTat mice at 6 and 12 months
--using Figures 3c and 3d of BioRxiv 2020, representing results in 60
days old Snap25-IRES2-Cre mice crossed to Ai14 mice, as the
Respondent's own data in Figure 6 of U01 DA056010-01 and Figure 8 of
R01 AG078019-01, representing results in 12-weeks old iTat mice
--using, cropping, and splicing Figures 5g-5i of BioRxiv 2020,
representing cell type transcription factors networks signature of the
regulatory genome in neurons isolated from the brains of Snap25-IRES2-
Cre mice crossed to Ai14 mice, as the Respondent's own data in one
research record intended for use in preparing figures for incorporation
in U01 DA056010-01, representing spatiotemporal atlas of gene
regulatory networks and biological pathways in the brain during
neurogenesis and aging altered by Tat expression and HIV infection
fabricated and plagiarized research data and text that
described the research by:
--using Figure 3 of Front Onc 2021 as the Respondent's own data in
Figure 8 of U01 DA056010-01 and Figure 10 of R01 AG078019-01
plagiarized text by:
--using a paragraph from Sci Adv 2019 as the Respondent's own text
describing cocaine use disorder in the section titled ``The problem
description and a new therapeutic strategy for CUD in people living
with HAND'' of DP1 DA056160-01
--using a paragraph from Clin Trans Med 2017 as the Respondent's own
text describing single cell sequencing in Specific Aim 2 of both U01
DA056010-01 and R01 AG078019-01
Dr. He entered into a Voluntary Settlement Agreement (Agreement)
and voluntarily agreed to the following:
(1) Respondent will have his research supervised for a period of
three (3) years beginning on April 17, 2023 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
[[Page 27905]]
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of 2-3 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for a period of three (3) years from the effective date of the
Agreement. The committee will review primary data from Respondent's
laboratory on a quarterly basis and submit a report to ORI at six (6)-
month intervals setting forth the committee meeting dates and
Respondent's compliance with appropriate research standards and
confirming the integrity of Respondent's research.
ii. The committee will conduct an advance review of each
application for PHS funds, or report, manuscript, or abstract involving
PHS-supported research in which Respondent is involved. The review will
include a discussion with Respondent of the primary data represented in
those documents and will include a certification to ORI that the data
presented in the proposed application, report, manuscript, or abstract
are supported by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude himself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
Dated: April 28, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2023-09355 Filed 5-2-23; 8:45 am]
BILLING CODE 4150-31-P